GLP-1
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
Bound to the GLP-1 receptor, GLP-1 has an <scene name='10/1067195/Glp1_only/1'>alpha-helical structure</scene> that is <scene name='10/1067195/Cv1/1'>bent</scene> near glycine in some complexes. In solution, GLP-1 is <scene name='10/1067195/Glp-1_solution/1'>alpha-helical in its center</scene> according to NMR data. Looking at the helix-propensity of the peptide sequence, the N-terminal part of Glp-1 (7-37) is less likely to be alpha-helical than the C-terminal half. | Bound to the GLP-1 receptor, GLP-1 has an <scene name='10/1067195/Glp1_only/1'>alpha-helical structure</scene> that is <scene name='10/1067195/Cv1/1'>bent</scene> near glycine in some complexes. In solution, GLP-1 is <scene name='10/1067195/Glp-1_solution/1'>alpha-helical in its center</scene> according to NMR data. Looking at the helix-propensity of the peptide sequence, the N-terminal part of Glp-1 (7-37) is less likely to be alpha-helical than the C-terminal half. | ||
| - | [[Image:GLP1 helix propensity.PNG | + | [[Image:GLP1 helix propensity.PNG]] |
== Synthesis through proglucagon processing== | == Synthesis through proglucagon processing== | ||
Revision as of 20:36, 20 December 2024
Glucagon-like peptide 1 (GLP-1) is a hormone involved in insulin regulation. It was discovered when researchers found that glucose in the digestive tract led to higher insulin levels than the same amount of glucose administered directly in the blood stream[1]. GLP-1 is produced in specialized cells in the intestine and in the pancreas, is released into the blood and has effects on cells in the pancreas, in the brain, and in many other organs. The half-life of GLP-1 is on the order of minutes, so it exerts a short-term effect unless continuously produced.
| |||||||||||
References
- ↑ Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-130. PMID:31767182 doi:10.1016/j.molmet.2019.09.010
- ↑ Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009 Mar;296(3):E415-21. PMID:19116373 doi:10.1152/ajpendo.90887.2008
- ↑ Ramzy A, Kieffer TJ. Altered islet prohormone processing: a cause or consequence of diabetes? Physiol Rev. 2022 Jan 1;102(1):155-208. PMID:34280055 doi:10.1152/physrev.00008.2021
